



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/758,869	01/16/2004	Nusrallah Jubran	312951-P0051	8013
47604	7590	11/24/2008	EXAMINER	
DLA PIPER LLP US P. O. BOX 2758 RESTON, VA 20195			DOE, JANIS L.	
			ART UNIT	PAPER NUMBER
			1795	
		MAIL DATE	DELIVERY MODE	
		11/24/2008	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Attachment to Advisory Action PTOL-303:

1. For purposes of appeal, the proposed amendment filed on Nov. 10, 2008, will be entered and the proposed rejection detailed below will be included in the Examiner's Answer. To be complete, this rejection must be addressed in any brief on appeal.

Upon entry of the amendment for purposes of appeal:  
Claims 1-4, 6-12, and 14-16 would be rejected for the reasons set forth in paragraph 5 of the Final Office action mailed Sep. 9, 2008.

Paragraph 5:

Claims 1-4, 6-12, and 14-16 would be rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, for the reasons discussed in paragraph 5 of the Final Office action.

2. The objections to claims 1 and 9 set forth in the Final Office action mailed on Sep. 9, 2008, paragraph 6, would be withdrawn in response to the amendments to claims 1 and 9 set forth in the amendment filed on Nov. 10, 2008, which will be entered upon the filing of an appeal.

On further review, the rejection of claims 5 and 13 under

35 U.S.C. 112, first paragraph, set forth in the Final Office action mailed on Sep. 9, 2008, paragraph 5, would be withdrawn.

Accordingly, claims 5 and 13 would be objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

3. Applicants' arguments filed in the amendment filed on Nov. 10, 2008, after the mailing of the Final Office action on Sep. 9, 2008, regarding the 35 U.S.C. 112, first paragraph, rejection of claims 1-4, 6-12, and 14-16, set forth in the Final Office action, paragraph 5, are not persuasive for the reasons set forth in the Final Office action.

In addition, contrary to applicants' assertions in the arguments filed on Nov. 10, 2008, the two particular disclosed species, i.e., chemical compounds (2) and (3), at page 24 of the instant specification, do not provide an adequate written description of the generic charge transport compound formula (1) broadly recited in instant claims 1 and 9. As noted by applicants, the chemical compounds (2) and (3) are "non-limiting examples of suitable charge transport materials within the structure of Formula (1)" (emphasis added). As noted by applicants, when chemical compounds (2) and (3) are represented

by formula (1), both  $Y_1$  and  $Y_2$  are carbazolyl or the Cl-substituted carbazolyl, both  $X_1$  and  $X_2$  are methylene, where each methylene is bonded to the nitrogen atom of the respective carbazolyl  $Y_1$  and  $Y_2$ , both  $E_1$  and  $E_2$  are epoxy, and  $Z$  is a "bond." The generic formula (1) recited in instant claims 1 and 9 is broader than the two particular chemical compounds (2) and (3) because for the reasons discussed in the paragraph 5 of the Final Office action, the generic formula (1) includes compounds that are not the two disclosed species of compounds (2) and (3). For example, as discussed on page 5 of the Final Office action, in the generic formula (1), claims 1 and 9 recites that " $Y_1$  and  $Y_2$  comprise . . . a carbazolyl group." The term "comprise" in the recitation that " $Y_1$  and  $Y_2$  comprise, each independently, a carbazolyl group" (emphasis added) is open and includes, not only the  $Y$  groups being a carbazolyl group, but also includes any group that comprises a carbazolyl group. The generic formula (1) recited in instant claims 1 and 9 also includes charge transport compounds in which  $X_1$  and  $X_2$  are both bonds, when the integer "m" is 0, and  $E_1$  and  $E_2$  are bonded to the nitrogen atom of the carbazolyl group in  $Y_1$  and  $Y_2$ , respectively. Applicants have not indicated where in the originally filed specification there is an adequate written description of the charge transport material formula (1) where " $X_1$  is bonded to the

nitrogen of the carbazolyl group in  $Y_1$  and  $X_2$  is bonded to the nitrogen of the carbazolyl group in  $Y_2''$  broadly recited in instant claims 1 and 9.

The rejection of claims 1-4, 6-12, and 14-16 stands.